1. Home
  2. TLS vs FHTX Comparison

TLS vs FHTX Comparison

Compare TLS & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telos Corporation

TLS

Telos Corporation

HOLD

Current Price

$4.30

Market Cap

303.9M

Sector

Technology

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$5.75

Market Cap

332.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLS
FHTX
Founded
1969
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
303.9M
332.2M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
TLS
FHTX
Price
$4.30
$5.75
Analyst Decision
Buy
Strong Buy
Analyst Count
5
7
Target Price
$7.75
$11.71
AVG Volume (30 Days)
715.4K
111.3K
Earning Date
01-01-0001
04-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.48
EPS
N/A
N/A
Revenue
$108,272,000.00
$22,602,000.00
Revenue This Year
$52.26
$40.87
Revenue Next Year
$19.65
$11.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.83
$2.94
52 Week High
$8.36
$6.95

Technical Indicators

Market Signals
Indicator
TLS
FHTX
Relative Strength Index (RSI) 44.23 53.30
Support Level $3.82 $4.44
Resistance Level $5.95 $5.85
Average True Range (ATR) 0.26 0.34
MACD 0.07 -0.00
Stochastic Oscillator 51.65 73.76

Price Performance

Historical Comparison
TLS
FHTX

About TLS Telos Corporation

Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: